IL2 and neoplasm: The chronopharmacology of interleukin-2 (IL-2) was shown in tumor-bearing rats, where constant rate infusions of IL-2 induced a 37.5% mortality rate and a 25% objective tumor response rate, whereas animals receiving a “day cycle” of IL-2 had no mortality and a 100% objective response rate [106].